Press Briefing on New Developments in Hepatitis C Treatment
|When:||Tuesday, October 15, 2013, 4:00 – 4:30 p.m. PDT|
|Where:||ACG Press Room (11B), San Diego Convention Center
Dial-ln Teleconference Access: U.S. Only. Toll-free: 1-888-850-4523. Participant code: 424049.
Kris V. Kowdley, M.D., FACG; Benaroya Research Institute, Seattle, WA
Fred Poordad, M.D., Texas Liver Institute, UT San Antonio
Christophe Moreno, Ph.D., Erasme Hospital, Brussels Belgium
|What:||Data on new treatment options and combinations of therapies to treat chronic viral hepatitis C infection will be presented by three research teams who reported on trials of several experimental treatments, including interferon-free drug combinations and direct acting antiviral agents effective against genotypes 2 and 3 of the hepatitis C virus, as well as new agents which have the potential to shorten the duration of therapy. These studies highlight how rapidly medical research is advancing in hepatitis C. The new wave of direct-acting agents has the potential to transform therapy for patients living with hepatitis C, both in terms of their safety and efficacy profiles, and also in terms of the possibility of reducing the duration of, or completely eliminating the need for, interferon injections.|
About the American College of Gastroenterology
Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of more than 12,000 individuals from 80 countries. The College’s vision is to be the pre-eminent professional organization that champions the evolving needs of clinicians in the delivery of high quality, evidence-based, and compassionate health care to gastroenterology patients. The mission of the College is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation and advocacy in the areas of scientific investigation, education, prevention and treatment. www.gi.org. View releases on research breaking at the ACG meeting and follow ACG on Twitter and share your live updates #acg2013.